Dr. Julie Lemieux is a hemato-oncologist at the CHU de Québec-Laval University. She is also a clinical researcher at the Research Center of the CHU de Québec-Laval University, and clinical professor at the Laval University School of Medicine. Dr. Lemieux is part of the research group of the Centre des Maladies du Sein of CHU de Québec-Laval University.

Dr. Lemieux is a member of the Canadian Clinical Trial Group for quality of life in breast cancer. She is also a scientific committee member for the McPeak-Sirois research group.

Using structured breast cancer data
The Centre des Maladies du Sein research team has a comprehensive database of all cancers diagnosed since 1974; more than 12,000 patients are listed. A database of biopsy data from 1999 is also available; data on more than 34,000 biopsies are listed. These databases allow quality publications that modify the management and monitoring of cancers and benign breast diseases.

Offer innovative treatments
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is one of the largest in Canada offering innovative treatments for breast cancer. More than 50 clinical trials are active at all times and are offered to patients who consult at the clinic or are referred by clinics/hospitals in the area. These clinical trials provide access to innovative experimental medications and develop the expertise of our world-renowned oncologists.

Support the quality of life
The Centre des Maladies du Sein of CHU de Québec-Laval University research group is a pioneer in quality of life studies in breast cancer, from total mastectomy to partial mastectomy, to the use of the cooling cap to counteract hair loss, promoting physical activity to improve survivorship, including optimal preservation of the axillary lymph nodes. The research group is at the forefront of studies promoting quality of life despite the adverse effects of the disease on an individual’s life.

Hôpital Saint-Sacrement
1050, chemin Sainte-Foy
Québec, Québec
Canada G1S 4L8
44 entries « 5 of 5 »

Au HJ, Ringash J, Brundage M, Palmer M, Richardson H, Meyer RM, NCIC CTG Quality of Life Committee

Added value of health-related quality of life measurement in cancer clinical trials: the experience of the NCIC CTG.

Journal Article

Expert Rev Pharmacoecon Outcomes Res, 10 (2), pp. 119-28, 2010, ISSN: 1473-7167 .

Abstract | Links:

Lemieux J, Clemons M, Provencher L, Dent S, Latreille J, Mackey J, Pritchard KI, Rayson D, Verma Sh, Verma S, Wang B, Chia S

The role of neoadjuvant (HER)2-targeted therapies in (HER)2-overexpressing breast cancers.

Journal Article

Curr Oncol, 16 (5), pp. 48-57, 2009, ISSN: 1198-0052.

Abstract | Links:

Dent S, Verma Sh, Latreille J, Rayson D, Clemons M, Mackey J, Verma S, Lemieux J, Provencher L, Chia S, Wang B, Pritchard K

The role of HER2-targeted therapies in women with HER2-overexpressing metastatic breast cancer.

Journal Article

Curr Oncol, 16 (4), pp. 25-35, 2009, ISSN: 1198-0052.

Abstract | Links:

Lemieux J, Amireault C, Provencher L, Maunsell E

Incidence of scalp metastases in breast cancer: a retrospective cohort study in women who were offered scalp cooling

Journal Article

Breast Cancer Res Treat, 118 (3), pp. 547-52, 2009, ISSN: 0167-6806.

44 entries « 5 of 5 »
Signaler des ajouts ou des modifications

Active projects

  • Age-related patterns in the experience of chemotherapy-induced peripheral neuropathy, Subvention, Instituts de recherche en santé du Canada, Subvention Projet, from 2019-10-01 to 2024-09-30
  • Centre de recherche du CHU de Québec - Université Laval, Subvention, Centre hospitalier universitaire de Québec - Université Laval, Centres de recherche affiliés, from 2017-01-01 to 2099-12-31
  • Perfectionism and psychosocial adjustment to cancer : A mixed methods study, Subvention, Conseil de recherches en sciences humaines du Canada, Programme Savoir: Subventions Savoir, from 2020-03-31 to 2024-03-31

Recently finished projects

  • LA LEAST Luminal A, limited endocrine adjuvant systemic therapy, a phase II trial of abbreviated hormone therapy for low risk hormone receptor positive, HER2 negative early breast cancer, Subvention, L'Institut de recherche de la Société canadienne du cancer, from 2017-04-01 to 2020-03-31
  • MA-12: Étude randomisée à double insu visant à comparer le tamoxifène avec un placebo chez les patientes atteintes d'un cancer du sein étendu aux ganglions lymphatiques et qui ont complété une chimiothérapie adjuvante ..., Subvention, L'Institut de recherche de la Société canadienne du cancer, Subvention de recherche, from 1997-04-01 to 2020-03-31
  • NSABP Breast Cancer Treatment Protocols, Subvention, National Institute of Health (USA), Subvention de recherche, from 1997-02-01 to 2020-01-31
  • PALbociclib CoLlaborative Adjuvant Study (PALLAS study), Subvention, L'Institut de recherche de la Société canadienne du cancer, from 2017-05-17 to 2020-03-31
Data provided by the Université Laval research projects registery